PL2024354T3 - Pochodne 1-[(4-[benzoilo(metylo)amino]-3-(fenylo)butylo]azetydyny do leczenia zaburzeń żołądkowo-jelitowych 1 - Google Patents

Pochodne 1-[(4-[benzoilo(metylo)amino]-3-(fenylo)butylo]azetydyny do leczenia zaburzeń żołądkowo-jelitowych 1

Info

Publication number
PL2024354T3
PL2024354T3 PL07748146T PL07748146T PL2024354T3 PL 2024354 T3 PL2024354 T3 PL 2024354T3 PL 07748146 T PL07748146 T PL 07748146T PL 07748146 T PL07748146 T PL 07748146T PL 2024354 T3 PL2024354 T3 PL 2024354T3
Authority
PL
Poland
Prior art keywords
benzoyl
phenyl
butyl
amino
methyl
Prior art date
Application number
PL07748146T
Other languages
English (en)
Inventor
Anders Johansson
Johan Johansson
Carl-Gustav Sigfridsson
Original Assignee
Albireo Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38723558&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2024354(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Albireo Ab filed Critical Albireo Ab
Publication of PL2024354T3 publication Critical patent/PL2024354T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
PL07748146T 2006-05-18 2007-05-16 Pochodne 1-[(4-[benzoilo(metylo)amino]-3-(fenylo)butylo]azetydyny do leczenia zaburzeń żołądkowo-jelitowych 1 PL2024354T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80157706P 2006-05-18 2006-05-18
PCT/SE2007/000482 WO2007136324A1 (en) 2006-05-18 2007-05-16 1- [ (4- [benzoyl (methyl) amino] -3- (phenyl) butyl] azetidine derivatives for the treatment of gastrointestinal disorders 1
EP07748146A EP2024354B1 (en) 2006-05-18 2007-05-16 1- [ (4- [benzoyl (methyl) amino]-3- (phenyl) butyl]azetidine derivatives for the treatment of gastrointestinal disorders 1

Publications (1)

Publication Number Publication Date
PL2024354T3 true PL2024354T3 (pl) 2012-02-29

Family

ID=38723558

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07748146T PL2024354T3 (pl) 2006-05-18 2007-05-16 Pochodne 1-[(4-[benzoilo(metylo)amino]-3-(fenylo)butylo]azetydyny do leczenia zaburzeń żołądkowo-jelitowych 1

Country Status (24)

Country Link
US (1) US8106208B2 (pl)
EP (1) EP2024354B1 (pl)
JP (1) JP5196381B2 (pl)
KR (1) KR101429779B1 (pl)
CN (1) CN101472910B (pl)
AR (1) AR060956A1 (pl)
AT (1) ATE525355T1 (pl)
AU (1) AU2007253666B2 (pl)
BR (1) BRPI0712405A2 (pl)
CA (1) CA2652443C (pl)
DK (1) DK2024354T3 (pl)
ES (1) ES2373335T3 (pl)
HK (1) HK1121758A1 (pl)
IL (1) IL195197A (pl)
MX (1) MX2008014686A (pl)
MY (1) MY147474A (pl)
NO (1) NO20084674L (pl)
PL (1) PL2024354T3 (pl)
PT (1) PT2024354E (pl)
RU (1) RU2439067C2 (pl)
TW (1) TW200813006A (pl)
UY (1) UY30356A1 (pl)
WO (1) WO2007136324A1 (pl)
ZA (1) ZA200809909B (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR057828A1 (es) * 2005-09-29 2007-12-19 Astrazeneca Ab Compuestos derivados de azetidina, su preparacion y composicion farmaceuutica
US20100168103A1 (en) * 2006-09-14 2010-07-01 Neuromed Pharmaceuticals Ltd. Diaryl piperidine compounds as calcium channel blockers
RU2480453C2 (ru) 2007-03-08 2013-04-27 Альбирео Аб Новые соединения
JP5780954B2 (ja) * 2008-05-08 2015-09-16 エヴォテック・アクチエンゲゼルシャフト ヒスタミンh3受容体アンタゴニストとしてのアゼチジン類及びシクロブタン類
CN103260703A (zh) * 2010-10-22 2013-08-21 詹森药业有限公司 作为单酰甘油脂肪酶抑制剂的哌啶-4-基-氮杂环丁烷二酰胺
EP2760861A1 (en) * 2011-09-30 2014-08-06 Janssen Pharmaceutica, N.V. Crystalline hydrochloride salt of (1- (4 -fluorophenyl) - 1h - indol - 5 - yl) - (3- (4- (thiazole - 2 - carbonyl) piperazin- 1 - yl) az etidin- 1 -yl) methanone and its use in the treatment of pain and metabolic disorders
CN104529833B (zh) * 2014-12-10 2016-04-20 广东东阳光药业有限公司 取代的环丁烷羧酸类化合物及其用途
KR102476938B1 (ko) 2017-12-07 2022-12-13 기초과학연구원 핫전자 기반의 산화물-금속 하이브리드 역촉매

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9310066D0 (en) 1993-05-17 1993-06-30 Zeneca Ltd Alkyl substituted heterocycles
GB9310713D0 (en) 1993-05-24 1993-07-07 Zeneca Ltd Aryl substituted heterocycles
GB9317104D0 (en) 1993-08-17 1993-09-29 Zeneca Ltd Therapeutic heterocycles
GB9322643D0 (en) 1993-11-03 1993-12-22 Zeneca Ltd Lactam derivatives
GB9325074D0 (en) 1993-12-07 1994-02-02 Zeneca Ltd Bicyclic heterocycles
TW432061B (en) 1994-08-09 2001-05-01 Pfizer Res & Dev Lactams
GB9502644D0 (en) 1995-02-10 1995-03-29 Zeneca Ltd Heterocyclic derivatives
GB9600235D0 (en) 1996-01-05 1996-03-06 Pfizer Ltd Therapeutic agents
GB9601202D0 (en) 1996-01-22 1996-03-20 Pfizer Ltd Piperidones
GB9601697D0 (en) 1996-01-27 1996-03-27 Pfizer Ltd Therapeutic agents
GB9601680D0 (en) 1996-01-27 1996-03-27 Pfizer Ltd Therapeutic agents
GB9714129D0 (en) 1997-07-04 1997-09-10 Pfizer Ltd Azetidines
GB9812037D0 (en) 1998-06-04 1998-07-29 Pfizer Ltd Piperidones
BR9912013A (pt) 1998-07-10 2001-04-10 Astrazeneca Ab Composto, composição farmacêutica, método de tratar uma condição de doença, e, processo para preparar um composto
GB9922521D0 (en) 1998-10-07 1999-11-24 Zeneca Ltd Compounds
GB9922519D0 (en) 1998-10-07 1999-11-24 Zeneca Ltd Compounds
GB9924141D0 (en) 1998-10-30 1999-12-15 Zeneca Ltd Treatment of gastric asthma
GB9826941D0 (en) 1998-12-09 1999-02-03 Zeneca Pharmaceuticals Compounds
SE0004827D0 (sv) 2000-12-22 2000-12-22 Astrazeneca Ab Therapeutic compounds
SE0103795D0 (sv) 2001-11-02 2001-11-02 Astrazeneca Ab Compounds and method for the treatment of överactive bladder
TW200508221A (en) 2003-06-13 2005-03-01 Astrazeneca Ab New azetidine compounds
WO2006137790A1 (en) * 2005-06-23 2006-12-28 Astrazeneca Ab New azetidine derivatives as neurokinin receptor antagonists for the treatment of gastrointestinal diseases
JP2008546768A (ja) * 2005-06-23 2008-12-25 アストラゼネカ・アクチエボラーグ 胃腸疾患を治療するためのニューロキニン受容体アンタゴニストとしての新規なアゼチジン誘導体
AR057828A1 (es) * 2005-09-29 2007-12-19 Astrazeneca Ab Compuestos derivados de azetidina, su preparacion y composicion farmaceuutica
AR056087A1 (es) * 2005-09-29 2007-09-19 Astrazeneca Ab Derivados de azetidina como antagonistas de receptores de neuroquina nk

Also Published As

Publication number Publication date
UY30356A1 (es) 2008-01-02
AU2007253666B2 (en) 2012-03-15
MX2008014686A (es) 2009-02-10
US8106208B2 (en) 2012-01-31
DK2024354T3 (da) 2012-01-16
RU2439067C2 (ru) 2012-01-10
IL195197A (en) 2013-10-31
CA2652443C (en) 2014-01-14
AR060956A1 (es) 2008-07-23
IL195197A0 (en) 2009-08-03
AU2007253666A1 (en) 2007-11-29
PT2024354E (pt) 2011-12-19
HK1121758A1 (en) 2009-04-30
US20070270398A1 (en) 2007-11-22
NO20084674L (no) 2009-01-29
CA2652443A1 (en) 2007-11-29
CN101472910B (zh) 2014-03-26
JP5196381B2 (ja) 2013-05-15
EP2024354A1 (en) 2009-02-18
MY147474A (en) 2012-12-14
JP2009537516A (ja) 2009-10-29
CN101472910A (zh) 2009-07-01
EP2024354B1 (en) 2011-09-21
EP2024354A4 (en) 2009-11-11
RU2008149927A (ru) 2010-06-27
BRPI0712405A2 (pt) 2012-10-16
TW200813006A (en) 2008-03-16
ES2373335T3 (es) 2012-02-02
WO2007136324A1 (en) 2007-11-29
KR20090018926A (ko) 2009-02-24
ATE525355T1 (de) 2011-10-15
KR101429779B1 (ko) 2014-08-19
ZA200809909B (en) 2009-08-26

Similar Documents

Publication Publication Date Title
HK1121758A1 (en) 1- [ (4- [benzoyl (methyl) amino]-3- (phenyl) butyl]azetidine derivatives for the treatment of gastrointestinal disorders 1
HK1203959A1 (en) Method for the preparation of 4-[3-(4-cyclopropanecarbonyl- piperazine-1-carbonyl)-4-fluoro-benzyl -2h-phthalazin-1-one 1-()-4-[5-[(34--4--1-) -2-
ZA200706697B (en) 3, 4-Substituted pyrrolidine derivatives for the treatment of hypertension
EP1833467A4 (en) PHARMACEUTICAL COMPOSITIONS FOR SLEEP DISORDERS
GB0520751D0 (en) Pharmaceutical compositions for the treatment of chronic obstructive pulmonary disease
EP1740559A4 (en) 1,3,5-SUBSTITUTED PHENYL DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE FOR THE TREATMENT OF ALZHEIMER'S DISEASE
ZA200710611B (en) New azetidine derivatives as neurokinin receptor antagonists for the treatment of gastrointestinal diseases
IL177937A0 (en) 3-[4-heterocyclyl-1,2,3-triazol-1-yl]-n-aryl-benzamides as inhibitors of the cytokines production for the treatment of chronic inflammatory diseases
IL187787A0 (en) Salts of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
GB0522311D0 (en) Pharmaceutical compositions for the treatment of pain
IL194744A (en) Derivatives 1– (alkyl) –3– (amino-converted) –5– (converted) - s-triazole, a process for their preparation and pharmacological preparations containing them for the treatment of psychotic diseases
ZA200700685B (en) Novel piperidine derivative for the treatment of depression
IL192024A0 (en) 3,5-substituted piperidine compounds as renin inhibitors
PL2167085T3 (pl) 4-[2-(4-metylofenylosulfanylo)fenylo]piperydyna do leczenia zespołu nadwrażliwości jelita grubego (ibs)
IL186130A0 (en) 3,4,5-substituted piperidines as renin inhibitors
IL186124A0 (en) 3,4,5-substituted piperidines as renin inhibitors
EP1899318A4 (en) NEW AZETIDINE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS FOR THE TREATMENT OF STOMACH DARM DISEASES
IL184885A0 (en) 7-{4-[2-(2,6-dihydro-4-methylphenoxy)ethoxyl]phenyl}-3,9-diazabicyclo[3.3.31]non-6-ene-s-carboxylic acid cyclopropyl-(2,3-dimethylbenzyd amide as inhibitors of renin for the treatment of hypertension
IL179346A0 (en) 3-(4-(2-dihydroisoxazol-3-ylpyridin-5-yl)phenyl)-5-triazol-1-ylmethyloxazolidin-2-one derivatives as mao inhibitors for the treatment of bacterial infections
ZA200805159B (en) Imidazole derivatives for the treatment of gastrointestinal disorders
IL180336A0 (en) Crystal forms of (3r) -1 - (2 - methylalanyl - d - tryptophyl) - 3 -(phenylmethyl)-3- piperidinecarboxylic acid 1, 2, 2 - trimethylhydrazide
DK1848731T3 (da) Antibiotika 107891, dets faktorer, farmaceutisk acceptable salte og sammensætninger og anvendelse heraf
ME01609B (me) Roflumilast za liječenje pulmonarne hipertenzije
HK1098059A1 (en) Composition comprising itraconazole for oral administration
TWI340643B (en) 1-[2h-1-benzopyran-2-one-8-yl]-piperazine derivatives for the treatment of movement disorders